Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Acute Respiratory Failure in Obesity-Hypoventilation Syndrome Managed in the ICU.

Chebib N, Nesme P, Freymond N, Argaud L, Rimmelé T, Bohé J, Devouassoux G, Souquet PJ, Guérin C.

Respir Care. 2019 Sep 10. pii: respcare.06901. doi: 10.4187/respcare.06901. [Epub ahead of print]

PMID:
31506342
2.

Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.

Souquet PJ, Couraud S.

Lancet Oncol. 2019 Aug 14. pii: S1470-2045(19)30508-X. doi: 10.1016/S1470-2045(19)30508-X. [Epub ahead of print] No abstract available.

PMID:
31422027
3.

Relationship between food behavior and taste and smell alterations in cancer patients undergoing chemotherapy: A structured review.

Drareni K, Dougkas A, Giboreau A, Laville M, Souquet PJ, Bensafi M.

Semin Oncol. 2019 Apr;46(2):160-172. doi: 10.1053/j.seminoncol.2019.05.002. Epub 2019 Jun 4. Review.

PMID:
31204004
4.

Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.

Swalduz A, Souquet PJ, Pérol M, Moro-Sibilot D, Schiffler C, Chabaud S, Fayet Y, Rogasik M, Labrosse H, Farsi F, Brun P, Decroisette C, Bombaron P, Bringuier PP, Haddad V, Forest F, Peoc'h M, Lantuejoul S, de Fraipont F, Ray-Coquard I, Fournel P.

Future Oncol. 2019 Jun;15(18):2139-2149. doi: 10.2217/fon-2018-0943. Epub 2019 Jun 12.

PMID:
31185741
5.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors.

Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8.

PMID:
31181537
6.

Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.

Garcia J, Wozny AS, Geiguer F, Delherme A, Barthelemy D, Merle P, Tissot C, Jones FS, Johnson C, Xing X, Xu Z, Edelstein DL, Brevet M, Souquet PJ, Rodriguez-Lafrasse C, Payen L, Couraud S.

Cancer Med. 2019 Jul;8(8):3685-3697. doi: 10.1002/cam4.2244. Epub 2019 May 21.

7.

Is Nutritional Screening of Patients with Lung Cancer Optimal? An Expert Opinion Survey of French Physicians and Surgeons.

Corbaux P, Fontaine-Delaruelle C, Souquet PJ, Couraud S, Morel H, Tronc F, Eker E, Peron J, Raynard B.

Nutr Cancer. 2019;71(6):971-980. doi: 10.1080/01635581.2019.1595051. Epub 2019 May 9.

PMID:
31070050
8.

Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.

Antoun S, Morel H, Souquet PJ, Surmont V, Planchard D, Bonnetain F, Foucher P, Egenod T, Krakowski I, Gaudin H, Debieuvre D.

J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):782-793. doi: 10.1002/jcsm.12418. Epub 2019 Apr 1.

9.

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.

Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ.

J Thorac Oncol. 2019 May;14(5):903-913. doi: 10.1016/j.jtho.2019.01.008. Epub 2019 Jan 18.

PMID:
30664989
10.

A retrospective study of factors associated with treatment decision for nontuberculous mycobacterial lung disease in adults without altered systemic immunity.

Provoost J, Valour F, Gamondes D, Roux S, Freymond N, Perrot E, Souquet PJ, Kiakouama-Maleka L, Chidiac C, Lina G, Dumitrescu O, Sénéchal A, Ader F.

BMC Infect Dis. 2018 Dec 14;18(1):659. doi: 10.1186/s12879-018-3559-x.

11.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C.

BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.

12.

[Oral and mucosal lichenoid drug eruption under anti-PD-1].

Amini-Adle M, Balme B, Locatelli-Sanchez M, Souquet PJ, Dalle S.

Ann Dermatol Venereol. 2018 Nov;145(11):725-727. doi: 10.1016/j.annder.2018.07.004. Epub 2018 Aug 17. French. No abstract available.

PMID:
30126642
13.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet PJ.

ESMO Open. 2018 Jul 23;3(5):e000394. doi: 10.1136/esmoopen-2018-000394. eCollection 2018.

14.

High-fidelity simulation self-training enables novice bronchoscopists to acquire basic bronchoscopy skills comparable to their moderately and highly experienced counterparts.

Veaudor M, Gérinière L, Souquet PJ, Druette L, Martin X, Vergnon JM, Couraud S.

BMC Med Educ. 2018 Aug 7;18(1):191. doi: 10.1186/s12909-018-1304-1.

15.

Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.

Armoiry X, Tsertsvadze A, Connock M, Royle P, Melendez-Torres GJ, Souquet PJ, Clarke A.

PLoS One. 2018 Jul 25;13(7):e0199575. doi: 10.1371/journal.pone.0199575. eCollection 2018.

16.

Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management.

Confavreux CB, Pialat JB, Bellière A, Brevet M, Decroisette C, Tescaru A, Wegrzyn J, Barrey C, Mornex F, Souquet PJ, Girard N.

Joint Bone Spine. 2019 Mar;86(2):185-194. doi: 10.1016/j.jbspin.2018.03.005. Epub 2018 Apr 6.

PMID:
29631067
17.

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ.

PLoS One. 2017 Aug 25;12(8):e0182798. doi: 10.1371/journal.pone.0182798. eCollection 2017.

18.

Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma.

Maury JM, Girard N, Tabutin M, Grima R, Chalabreysse L, Pavlakovic I, Sayag-Beaujard A, Leroux C, Souquet PJ, Glehen O, Tronc F.

Lung Cancer. 2017 Jun;108:1-6. doi: 10.1016/j.lungcan.2017.02.014. Epub 2017 Feb 24.

PMID:
28625619
19.

Design features of offshore oil production platforms influence their susceptibility to biocorrosion.

Duncan KE, Davidova IA, Nunn HS, Stamps BW, Stevenson BS, Souquet PJ, Suflita JM.

Appl Microbiol Biotechnol. 2017 Aug;101(16):6517-6529. doi: 10.1007/s00253-017-8356-8. Epub 2017 Jun 8.

PMID:
28597336
20.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.

Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.

PMID:
28327934
21.

[Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].

Baudouin A, Fargier E, Cerruti A, Dubromel A, Vantard N, Ranchon F, Schwiertz V, Salles G, Souquet PJ, Thomas L, Bérard F, Nancey S, Freyer G, Trillet-Lenoir V, Rioufol C.

Bull Cancer. 2017 Jun;104(6):538-551. doi: 10.1016/j.bulcan.2017.01.006. Epub 2017 Feb 23. French.

PMID:
28237353
22.

Implementing flexible bronchoscopy in least developed countries according to international guidelines is feasible and sustainable: example from Phnom-Penh, Cambodia.

Veaudor M, Couraud S, Chan S, Choun C, Keo P, Avrillon V, Souquet PJ, Ny C.

BMC Pulm Med. 2017 Jan 10;17(1):10. doi: 10.1186/s12890-016-0354-6.

23.

[Predictive factors of complications during CT-guided transthoracic biopsy].

Fontaine-Delaruelle C, Souquet PJ, Gamondes D, Pradat E, de Leusse A, Ferretti GR, Couraud S.

Rev Pneumol Clin. 2017 Apr;73(2):61-67. doi: 10.1016/j.pneumo.2016.12.001. Epub 2017 Jan 4. French.

PMID:
28063634
24.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

Monnet I, Audigier-Valette C, Girard N, Vergnenègre A, Molinier O, Souquet PJ, Blanchon F, Bonnetain F, Taguieva-Pioger N, Lamour C, Wislez M.

Lung Cancer. 2016 Aug;98:84-90. doi: 10.1016/j.lungcan.2016.05.016. Epub 2016 May 26.

PMID:
27393512
25.

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur Respir J. 2016 Sep;48(3):861-72. doi: 10.1183/13993003.01695-2015. Epub 2016 Jun 23.

26.

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE.

Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.

27.

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

Walter T, Planchard D, Bouledrak K, Scoazec JY, Souquet PJ, Dussol AS, Guigay J, Hervieu V, Berdelou A, Ducreux M, Arpin D, Lombard-Bohas C, Baudin E.

Lung Cancer. 2016 Jun;96:68-73. doi: 10.1016/j.lungcan.2016.03.018. Epub 2016 Mar 31.

PMID:
27133753
28.

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE.

Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.

29.

Inequalities in lung cancer: a world of EGFR.

Carbonnaux M, Souquet PJ, Meert AP, Scherpereel A, Peters M, Couraud S.

Eur Respir J. 2016 May;47(5):1502-9. doi: 10.1183/13993003.01157-2015. Epub 2016 Mar 30.

30.

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.

Deplanque G, Gervais R, Vergnenegre A, Falchero L, Souquet PJ, Chavaillon JM, Taviot B, Fraboulet G, Saal H, Robert C, Chosidow O; CYTAR investigators.

J Am Acad Dermatol. 2016 Jun;74(6):1077-85. doi: 10.1016/j.jaad.2016.01.019. Epub 2016 Mar 4.

PMID:
26946985
31.

[Metastatic bronchial carcinoid tumors].

Bouledrak K, Walter T, Souquet PJ, Lombard-Bohas C.

Rev Pneumol Clin. 2016 Feb;72(1):41-8. doi: 10.1016/j.pneumo.2015.12.002. Epub 2016 Jan 30. Review. French.

PMID:
26831129
32.

[Long-term results of lung cancer surgery in octogenarians].

Gardet E, Tabutin M, Couraud S, Maury JM, Guibert B, Nguyen Van M, Tchalla AE, Souquet PJ, Tronc F.

Rev Pneumol Clin. 2016 Feb;72(1):3-9. doi: 10.1016/j.pneumo.2015.09.005. Epub 2015 Dec 24. French.

PMID:
26725006
33.

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Grard S, Catho G, Valour F, Bouaziz A, Perpoint T, Braun E, Biron F, Miailhes P, Ferry T, Chidiac C, Souquet PJ, Couraud S, Lina G, Goutelle S, Veziris N, Dumitrescu O, Ader F.

Open Forum Infect Dis. 2015 Dec 22;2(4):ofv175. doi: 10.1093/ofid/ofv175. eCollection 2015 Dec.

34.

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N, Souquet PJ.

Lung Cancer. 2016 Jan;91:23-8. doi: 10.1016/j.lungcan.2015.11.006. Epub 2015 Nov 15.

PMID:
26711930
35.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT Team.

Eur J Cancer. 2016 Jan;52:181-7. doi: 10.1016/j.ejca.2015.10.072. Epub 2015 Dec 12.

PMID:
26689864
36.

[Script concordance test for knowledge assessment of lung cancer screening].

Couraud S, Girard P, Girard N, Souquet PJ, Coiffard B, Charlin B, Milleron B.

Rev Mal Respir. 2016 May;33(5):333-42. doi: 10.1016/j.rmr.2015.09.001. Epub 2015 Oct 23. French.

PMID:
26603957
37.

[Economic impact of lung cancer screening in France: A modeling study].

Gendarme S, Perrot É, Reskot F, Bhoowabul V, Fourre G, Souquet PJ, Milleron B, Couraud S.

Rev Mal Respir. 2017 Sep;34(7):717-728. doi: 10.1016/j.rmr.2015.10.004. Epub 2015 Nov 12. French.

PMID:
26585377
38.

Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.

Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, Pérol M, Zavadil J, Brambilla C, Olivier M, Couraud S.

Eur Respir J. 2015 Dec;46(6):1773-80. doi: 10.1183/13993003.00676-2015. Epub 2015 Oct 22.

39.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.

Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17.

40.

[Endobronchial ultrasound transbronchial needle aspiration initiation into the Lyon Sud hospital center: Experience of the first three years].

Laffay L, Gérinière L, Couraud S, Souquet PJ.

Rev Pneumol Clin. 2016 Feb;72(1):17-24. doi: 10.1016/j.pneumo.2015.03.006. Epub 2015 Aug 21. French.

PMID:
26305022
41.

[Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].

Torrecillas S, Perrot E, Gérinière L, Locatelli-Sanchez M, Laffay L, Souquet PJ, Couraud S.

Rev Pneumol Clin. 2016 Feb;72(1):25-34. doi: 10.1016/j.pneumo.2015.03.005. Epub 2015 Jul 22. French.

PMID:
26210879
42.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G.

Lung Cancer. 2015 Aug;89(2):139-45. doi: 10.1016/j.lungcan.2015.05.016. Epub 2015 May 27.

PMID:
26059274
43.

Lung cancer may increase serum procalcitonin level.

Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, Desseigne M, Freymond N, Geriniere L, Perrot E, Souquet PJ, Couraud S.

Infect Disord Drug Targets. 2015;15(1):57-63.

PMID:
25809625
44.

No impact of passive smoke on the somatic profile of lung cancers in never-smokers.

Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ; BioCAST/IFCT-1002 study investigators.

Eur Respir J. 2015 May;45(5):1415-25. doi: 10.1183/09031936.00097314. Epub 2015 Mar 5.

45.

Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting.

Catho G, Couraud S, Grard S, Bouaziz A, Sénéchal A, Valour F, Perpoint T, Braun E, Biron F, Ferry T, Chidiac C, Freymond N, Perrot E, Souquet PJ, Maury JM, Tronc F, Veziris N, Lina G, Dumitrescu O, Ader F; Lyon TB Study Group.

Clin Microbiol Infect. 2015 May;21(5):472.e7-10. doi: 10.1016/j.cmi.2014.12.022. Epub 2015 Jan 20.

46.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS.

Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20.

47.

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF.

J Geriatr Oncol. 2015 May;6(3):233-40. doi: 10.1016/j.jgo.2015.02.002. Epub 2015 Feb 16.

PMID:
25698450
48.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT); French Cooperative Thoracic Intergroup IFCT.

Ann Oncol. 2015 May;26(5):908-14. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.

PMID:
25688059
49.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; French Cooperative Intergroup IFCT.

Eur Respir J. 2015 May;45(5):1403-14. doi: 10.1183/09031936.00097214. Epub 2015 Feb 5.

50.

[Assessment of a tool for decision making in case of worsening condition of cancer patients].

Toffart AC, Sakhri L, Girard N, Couraud S, Merle P, Fournel P, Perol M, Souquet PJ, Timsit JF, Moro-Sibilot D.

Rev Mal Respir. 2015 Jan;32(1):66-72. doi: 10.1016/j.rmr.2014.02.006. Epub 2014 Mar 20. French.

PMID:
25618207

Supplemental Content

Loading ...
Support Center